In re Abbott Laboratories Coronary and Peripheral Stent Litigations
Medical technology company Medtronic agreed to pay $400 million to Abbott Laboratories as part of a settlement ending 12 years of intellectual property lawsuits over the design and use of coronary and peripheral stents – tiny metal mesh devices used in the treatment of coronary artery disease.
Abbott counsel Finnegan, Henderson, Farabow, Garrett & Dunner, LLP retained Analysis Group to assess patent infringement damages in several of these stent litigations. Managing Principals Carla Mulhern and Justin McLean supported affiliates Sharon Oster and Ashley Stevens in their preparation of expert reports and deposition testimony on economic damages associated with alleged infringement of certain stent designs. Mr. McLean and Vice President Robin Heider also supported Managing Principal Laura Stamm, who provided an expert report and deposition testimony on damages in a stent matter between Medtronic and Abbott.
In addition to the monetary settlement, Abbott and Medtronic agreed to abstain from further litigation over coronary stents for at least 10 years, subject to certain conditions.